Latest News
Genmab reports positive safety data for Rina-S combination in ovarian cancer
13 April 2026 - Denmark-based biotechnology company Genmab A/S (Nasdaq: GMAB) reported on Monday that its Phase 1/2 RAINFOL-01 data showed that rinatabart sesutecan (Rina-S) in combination with bevacizumab demonstrated a tolerable safety profile in p...
GSK reports strong early-stage data for B7-H4 ADC in gynaecological cancers
13 April 2026 - Biopharmaceutical company GSK plc (LSE: GSK) (NYSE: GSK) on Monday announced positive results from its global phase I BEHOLD-1 trial evaluating mocertatug rezetecan (Mo-Rez), a B7-H4-targeted antibody-drug conjugate, in gynaecological...
EKF Diagnostics acquires Beep Insights technology to expand sports performance offering
13 April 2026 - Life sciences company EKF Diagnostics Holdings plc (AIM: EKF) has acquired technology assets from Sweden-based Beep Insights AB, including its iOS and Android application designed for real-time glucose and lactate tracking in sports p...
Trellus Health renews licensing agreement with Pfizer
13 April 2026 - Healthcare company Trellus Health plc (AIM: TRLS) announced on Monday that it has renewed its licensing agreement with biopharmaceutical company Pfizer Inc, extending the use of its patient support educational content within Pfizer�...
FDA grants priority review to ifinatamab deruxtecan in small cell lung cancer
13 April 2026 - US pharmaceutical company Merck & Co Inc (NYSE:MRK), known as MSD outside the US and Canada, and Japanese healthcare company Daiichi Sankyo Co Ltd (TYO:4568) announced on Monday that the US Food and Drug Administration (FDA) has g...